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Impact of the e-prescribing system on the incidence and nature of drug-related problems 1 
in children in a Saudi hospital 2 
 3 
Abstract 4 
 5 
Objectives 6 
To determine the impact of a computerised physician order entry (CPOE) system on the drug-7 
related problems’ (DRPs) incidence and characteristics in hospitalised children in a Saudi 8 
hospital, and to compare DRPs incidence pre-/post-CPOE implementation. 9 
Methods 10 
An observational study. DRPs were identified by pharmacists, reviewing children’s (0-14 years) 11 
medical records on CPOE system, in paediatric wards and/or attending emergency department. 12 
DRPs preventability and severity were assessed. 13 
Results 14 
657 paediatric patients were included, with 235 (35.8%) experienced 328 DRPs, majority were 15 
preventable (99.7%,327). Difference in DRP incidence pre- and post-CPOE implementation 16 
(44.8% vs 35.8%, p<0.01) was significant.  17 
Conclusion 18 
The CPOE system has significantly reduced DRPs incidence in children in the study hospital.  19 
 20 
Keywords: Computerised physician order entry; CPOE; Drug-related problems; DRPs; Children; 21 
Incidence; hospitalised paediatric patients. 22 
 23 
 24 
 25 
 26 
 27 
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Introduction 28 
Computerised physician order entry (CPOE) has been recognised to reduce medication errors in 29 
adult and paediatric populations.[1-2]  30 
Previous studies have investigated the incidence of and the risk factors for DRPs in children 31 
admitted to the paediatric wards and/or attended the emergency department (ED) at the King 32 
Abdulaziz Medical City-Jeddah hospital (KAMC-J), pre-CPOE implementation in 2011.[3-4] The 33 
studies showed that DRPs were common in children at KAMC-J. Dosing and drug choice 34 
problems were the most frequently reported DRPs. [3-4]  35 
The use of CPOE at KAMC-J is relatively new and there is limited evidence on the impact of 36 
CPOE on the DRPs incidence in paediatric patients. Furthermore, there are limited comparable 37 
studies that have investigated DRPs in hospitalised children in Saudi Arabia following CPOE 38 
introduction. This study aimed to investigate the impact of the CPOE on DRPs incidence and 39 
characteristics in hospitalised children at KAMC-J, and to compare the DRPs incidence before 40 
and after CPOE-implementation. 41 
 42 
Methods 43 
An observational study was conducted on paediatric wards and ED at KAMC-J. Patient included 44 
were children aged 0-14 years admitted during the study period.  45 
We used the same methodology that has been reported previously in the pre-CPOE 46 
implementation studies [3-4] and is summarised below. 47 
Data were collected by pharmacists (excluding weekends/night shifts), over a four-month period 48 
(May–August 2016). Patients’ medical records on CPOE, including electronic prescriptions were 49 
reviewed. Patients not on medication on admission or during their stay were excluded. 50 
All identified DRPs were validated, assessed for severity and preventability and classified using 51 
the same assessment and classification tools used in the previous studies.[3-4] 52 
 53 
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The results of this study were compared with the findings of the previous studies conducted pre-54 
CPOE implementation.[3-4]  55 
 56 
Descriptive data analysis was performed. Data are presented as number, percentage and median 57 
(interquartile range, IQR), unless otherwise specified. Chi-squared test, Kruskal–Wallis rank and 58 
Wilcoxon rank sum (Mann–Whitney U test) were used as appropriate. Statistical significance was 59 
considered at p<0.05.  60 
DRP incidence was defined as; number of patients with at least one DRP divided by total number 61 
of patients in the study cohort, or by the number of patients in each ward, and multiplied by 100. 62 
The incidence was calculated with 95% confidence interval (CI).  63 
This study was approved by the Research Committee at King Abdullah International Medical 64 
Research Centre-Western Region (RJ15/043/J) in 2015. 65 
 66 
Results 67 
A total of 657 patients (median age 1.5 years, IQR 2-6 years) were included, 58.9% (387/657) 68 
were male. Overall, 328 confirmed DRPs were identified for 235 (35.8%) children, (Table 1). 69 
There was a significant difference in DRPs incidence between wards (p=0.031). The highest 70 
incidence was reported from ED (52.2%, 95%CI 41.4 – 62.9). 71 
Dosing problems (64.9%,213/328) were the most frequently reported DRPs, followed by drug 72 
choice problems (32.9%,108/328). This was the case in each study area, [supplementary table 73 
1]. The majority (74.2%,274/369) of reported causes of DRPS in each area were related to drug 74 
or dose selection. [Supplementary table 2] 75 
 76 
Majority of DRPs (95.1%,312/328) was found to be moderate in severity and 4.6% (15/328) were 77 
assessed as minor (Table 1). Only one DRP (0.3%,1/328) from ED was assessed as severe. This 78 
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was “inappropriate drug selection” problem; related to a patient prescribed ‘amoxicillin/enzyme 79 
inhibitor’ despite being documented as penicillin allergic.  80 
Almost all identified DRPs were deemed preventable (99.7%,327/328), (Table 1). Only one DRP 81 
was deemed not preventable, which was a side effect problem related to a high insulin dose which 82 
resulted in patient becoming hypoglycaemic.  83 
 84 
Significant difference in the DRP incidence was found between pre- and post-CPOE 85 
implementation (44.8% vs 35.8%, p<0.01), (Table 2).  86 
Almost all identified DRPs post-CPOE implementation (99.7%) were found to be preventable 87 
compared to 92.3% of DRPs in the pre-implementation studies, p<0.001. There was a significant 88 
difference in severity between the pre-and post-studies, p<0.01. In pre-CPOE implementation, 89 
69.0% (214/310) of DRPs were assessed as minor, while 95.1% (312/328) were moderate in 90 
severity post-CPOE. Drug choice problems were more frequent in the post-CPOE implementation 91 
(32.9% (108/328) vs 10.3% (32/310), while dosing problems were more frequent in pre-CPOE 92 
implementation study (72.6% (225/310) vs 64.9% (213/328)). Interaction problems were more 93 
frequent in pre-CPOE study (5.5% (17/310) vs 0.6% (2/328), p<0.001). [Supplementary table 3]  94 
 95 
Discussion 96 
Five years following CPOE implementation, this study showed that there was a reduction in DRPs 97 
occurrence. This is likely to be attributed to the CPOE, as it is the only change that has been 98 
made to the prescribing process at KAMC-J.  99 
To our knowledge, this is the first study to report on the DRPs incidence post-CPOE system 100 
implementation in a Saudi hospital, and to compare the incidence with the findings reported pre-101 
CPOE implementation. Also, to avoid variation in methodology and to be able to compare the pre- 102 
and post-CPOE implementation findings, this study adopted the same methodology and DRP 103 
classification that have been used in the pre-CPOE implementation studies.[3-4] However, certain 104 
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limitations must be considered when interpreting our results. The study was conducted at one 105 
institution; hence drawing on a single institution’s experience. The use of off-label/unlicensed 106 
medications was not considered in the analysis. Weekend/night shifts were excluded from data 107 
collection. Potential risk factors that might be confounders for DRPs occurrence were not 108 
investigated.  109 
 110 
Frequency of severe DRPs was lower post-CPOE, which suggests that CPOE contributed to the 111 
reduction of more severe DRPs. This has been seen in previous CPOE studies conducted in 112 
children.[5] Significant difference between dosing and interaction problems frequencies pre- and 113 
post-CPOE highlights the impact of CPOE in minimising such medication problems. Also, the 114 
reduction in the interaction problems frequency post-CPOE might be explained by the presence 115 
of “interaction alert” function built within the system. This in line with previous studies.[5]  116 
 117 
Though there has been a reduction in the DRPs incidence in this study, the reported incidence 118 
does show that DRPs in children at KAMC-J remain common. This might be attributed to the fact 119 
that different drug dosing references are still being used throughout KAMC-J.[6-10] In addition, 120 
the computerised clinical decision support (CCDS) built into CPOE is based on adult dosing 121 
formulary which might have contributed to the DRP occurrence.  122 
The lack of a specific paediatric dosing guidance built into CPOE might explain the persistence 123 
of the high number of dosing and drug choice problems in the current study. Therefore, 124 
incorporating a more paediatric specific CCDS into CPOE system may help in more reduction of 125 
potential DRPs leading to further improvement in patient safety. 126 
Other strategies to reduce DRPs frequency in hospitalised children and minimize their harmful 127 
consequences should also be considered, e.g. using standardized dose bands of antibiotics in 128 
children across the hospital.  129 
 130 
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Conclusion 131 
This observational study showed that the CPOE system might have resulted in the reduction of 132 
DRPs incidence in hospitalised children at KAMC-J. Majority of identified DRPs were dosing and 133 
drug choice problems, similar to pre-CPOE implementation findings, suggesting that incorporating 134 
a more paediatric specific CCSD into CPOE is necessary to further reduce these problems and 135 
improve the care provided to children. 136 
 137 
Funding: This research received no specific grant from any funding agency in the public, 138 
commercial, or not-for-profit sectors. 139 
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Table 1 Frequency and incidence of DRP in each study ward and overall, post-CPOE implementation  165 
 
NICU 
(n=88)* 
PICU 
(n=57)* 
Medical 
(n=204)*  
Surgical 
(n=218)* 
ED 
(n=90)* 
Overall  
(n=657) 
Number of DRPs (%) 35 (10.7) 40 (12.2) 106 (32.3) 86 (26.2) 61 (18.6) 328 (100) 
Number of patients by 
gender, n (%) 
      
Male 56 (63.6) 34 (59.6) 118 (57.8) 126 (57.8) 53 (58.9) 387 (58.9) 
Female 32 (36.4) 23 (40.4) 86 (42.2) 92 (42.2) 37 (41.1) 270 (41.1) 
Number of patients 
with DRP (%) 
26 (29.5) 22 (38.6) 78 (38.2) 62 (28.4) 47 (52.2) 235 (35.8) 
Age of children (in 
years) with DRPs; 
median (IQR) 
0.1 (0.04 -0.1) 0.3 (0.2 – 1.3) 2 (0.4 – 7) 4 (2 – 8) 
1.6 (0.3 – 5) 
 
1.6 (0.2 – 6) 
 
DRP incidence by 
gender; n (%)  
      
Male  17 (30.4) 13 (38.2) 42 (35.6)  35 (27.8) 28 (52.8) 135 (34.9) 
Female  9 (28.1) 9 (39.1) 36 (41.9) 27 (29.3) 19 (51.4) 100 (37.0) 
DRPs incidence; % 
(95% CI)  
29.5 (20.3 – 40.2) 38.6 (26.0 – 52.4) 38.2 (31.5 – 45.3) 28.4 (22.5 – 34.9) 52.2 (41.4 – 62.9) 35.8 (32.1 – 39.6) 
Severity       
Minor  - - 4 (3.8) 9 (10.5) 2 (3.3) 15 (4.6) 
Moderate  35 (100) 40 (100) 102 (96.2) 77 (89.5) 58 (95.1) 312 (95.1) 
Severe  - - - - 1 (1.6) 1 (0.3) 
Preventability; n (%)       
Preventable 35 (100) 40 (100) 106 (100) 85 (98.8) 61 (100) 327 (99.7) 
Not preventable  - - - 1 (1.2) - 1 (0.3) 
CPOE: Computerised Physician Order Entry; IQR: interquartile range; DRPs: Drug Related Problems; ED: Emergency Department; PICU: Paediatric 
Intensive Care Unit; NICU=Neonatal Intensive Care Unit; *n: total number of patients 
166 
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Table 2 Comparison of frequency and characteristics of identified DRPs  167 
 
Pre-CPOE  
n (%) 
Post-CPOE  
n (%) 
P value 
No. of DRPs 310  328 <0.01 
No. of patients with DRPs; n (%)a 227 (44.8) 235 (35.8)  
No. of patients with DRPs by 
gender; n (%) 
  0.760 
Female 94 (18.5) 100 (15.2)  
Male  133 (26.2) 135 (20.5)  
DRP incidence; % (95% CI)  44.8 (40.2 – 49.0) 35.8 (32.1 – 39.5) <0.01 
Severity of DRPs; n (%)   <0.001 
Minor  214 (69.0) 15 (4.6)  
Moderate 92 (29.7) 312 (95.1)  
Severe 4 (1.3) 1 (0.3)  
Preventability; n (%)   <0.001 
Preventable  286 (92.3) 327 (99.7)  
Not preventable 24 (7.7) 1 (0.3)  
a% calculated out of the total number of patients in each study cohort; pre-implementation=507; post-168 
implementation = 657; CPOE: Computerised Physician Order Entry; DRPs: Drug-related problems 169 
 170 
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